title: [The effect of cerebrolysin on cognitive functions in childhood autism and in Asperger syndrome].
abstract: Nineteen children with childhood autism and 8 with Asperger's syndrome aged 2-8 year, were treated with cerebrolysin (CL) in inpatient clinic. All the patients received 10 microinjections (intramuscularly and perinervously) of 0.1 ml CL daily during 5 days. Clinical study was combined with device estimation of cognitive functions and communicative skills. CL therapy resulted in improvement of cognitive functions (expressive and receptive speech, fine motoring, playing). Positive effects were revealed in all the patients with Asperger's syndrome and in 89% of the patients with childhood autism. Any negative effects were not found. With regard to cognitive functions development, therapeutic efficacy proved to be more pronounced in the patients with Asperger's syndrome as compared to childhood autistic group (p < 0.005).
authors.forename: M G
authors.initials: MG
authors.lastname: Krasnoperova
authors.forename: V M
authors.initials: VM
authors.lastname: Bashina
authors.forename: I A
authors.initials: IA
authors.lastname: Skvortsov
authors.forename: N V
authors.initials: NV
authors.lastname: Simashkova
mesh_terms: D000596:Amino Acids / Q000627:therapeutic use*; D020817:Asperger Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D001321:Autistic Disorder / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D003071:Cognition / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D018697:Nootropic Agents / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000596:Amino Acids; D018697:Nootropic Agents; C006952:cerebrolysin